Key Takeaways
- ARK divested 50,312 Rocket Lab shares valued at approximately $4 million via its ARKQ fund on April 27
- The transaction marks the second Rocket Lab reduction following last Friday’s disposal of over 113,000 shares
- ARK accumulated 263,848 Intellia Therapeutics shares totaling roughly $3.6 million through ARKK and ARKG funds
- The firm offloaded 13,806 Iridium Communications shares for approximately $538,000
- Rocket Lab shares climbed 3.28% Monday, finishing at $82.29 despite ARK’s divestment
Cathie Wood’s investment firm ARK Invest executed multiple strategic transactions on Monday, April 27, 2026, as revealed in the company’s routine fund activity reports.
The most significant transaction involved divesting 50,312 shares of Rocket Lab through the ARKQ exchange-traded fund, valued at approximately $4.01 million. This disposal occurred merely days following ARK’s previous Friday sale of more than 113,000 shares of the aerospace manufacturer.
Two consecutive sell-offs within such a brief timeframe indicate ARK is intentionally reducing its exposure to the space technology provider.
The notable aspect of this transaction is that Rocket Lab’s stock actually advanced 3.28% Monday, settling at $82.29. ARK strategically sold during an upswing rather than during a downturn.
The investment firm seems to be capitalizing on gains before Rocket Lab releases its first quarter 2026 financial results, slated for May 7, 2026.
Financial analysts on Wall Street anticipate Rocket Lab will announce quarterly revenues of $189.65 million, representing a 55% year-over-year increase. Forecasts also predict a loss of $0.07 per share, showing improvement compared to the $0.12 per share loss recorded in the corresponding quarter of the previous year.
ARK Increases Intellia Therapeutics Position
While reducing its Rocket Lab holdings, ARK aggressively acquired Intellia Therapeutics stock. The firm secured 263,848 shares distributed between its ARKK and ARKG exchange-traded funds, valued at approximately $3.6 million.
Intellia operates in the gene-editing sector, and its shares had declined 4.33% during Monday’s session. ARK seemingly capitalized on this decline as an entry point.
This strategy aligns with ARK’s established approach of increasing positions during temporary setbacks in companies it identifies as having substantial long-term growth potential.
Additionally, ARK disposed of 13,806 shares of Iridium Communications through its ARKX fund, totaling roughly $538,000. This move extends a developing pattern — ARK previously sold 33,315 Iridium shares on Friday and 81,422 shares the preceding Monday.
Wall Street’s Perspective on Rocket Lab
Notwithstanding ARK’s divestments, certain Wall Street analysts maintain optimistic outlooks on Rocket Lab.
Stifel analyst Erik Rasmussen elevated his price objective on the stock to $105 from $90 while maintaining a Buy recommendation. His rationale included consistent revenue expansion, a robust pipeline of contracted projects, and the anticipated debut of the Neutron rocket system this year.
Per TipRanks data, Rocket Lab presently carries a Moderate Buy consensus among analysts, supported by nine Buy recommendations and four Hold ratings accumulated during the last three months.
The consensus price target among analysts stands at $89.00, suggesting approximately 8% appreciation potential from present trading levels.
ARK’s subsequent daily transaction report will reveal whether the firm continued trimming its Rocket Lab stake on Tuesday.
